Medical Device Link.

Life sciences companies are actively exploring cross-sector opportunities for advancing healthcare by developing next-generation products, but are the business and policy environments ready?

Changes in patent law and recent court cases could have a significant effect on the ability of companies to create viable cross-sector ventures.

InHealth-funded research at Stanford University aims at providing scientific knowledge to support improvements in the regulatory environment.

Panelists | The Medical Device Development Process | InHealth-Stanford Study Methodology |
Cross-Sector Development: Conflict and Confusion

The funding environment for medical products couldn’t be better, but how will companies translate this support into next-generation products?

Life sciences ventures have the attention of angel and VC investors. This panel looks at what start-up or emerging companies should know when seeking funding partners, and what sectors investors consider hot today.

Creating a workable, robust, and flexible partnering arrangement requires imagination and visualization skills from everyone involved in the transaction.

The emergence of cross-sector ventures and combination products raises special issues—and opportunities—for regulatory agencies and third-party payers.

For companies developing combination products, a variety of regulatory challenges arise because of the regulatory, cultural, business, technological, and legal differences among the biotechnology, medical device, and pharmaceutical industries.

This presentation will look at how the value of next-generation cross-sector products and services will be determined, and what policy changes third-party payers should implement to streamline the development and adoption of new cross-sector medical solutions.

Getting reimbursement for new medical technologies involves more than just coverage, coding, and payment. This discussion will consider how companies should approach the tasks necessary to speed reimbursement.

Panelists | Recommended Reading

A proposed reimbursement critical path would result in rapid reimbursement decision making for novel, high-value technologies.

The increasing industry use of direct-to-consumer advertising can have an impact on the liability of manufacturers and on the learned intermediary defense.

Cross-sector partners need to outline the key elements of their product liability defense planning well in advance of any need to put it into effect. This panel will discuss current trends in product liability, including the imminent Supreme Court review of federal preemption of state tort laws.

The journey to creating a successful cross-sector venture begins by making contact.